ChiRhoClin Inc. announced that ChiRhoStim (human secretin for injection) has returned to the market. In cooperation with the FDA Center for Drug Evaluation and Research (CDER) Drug Shortage Team, ChiRhoClin is permitted to market the current batch of ChiRhoStim until its new manufacturing site is operational by the beginning of 2013.
ChiRhoStim is an orphan drug that aids in the diagnoses of pancreatic cancer and pancreatic exocrine dysfunction. Also, it is approved for pancreatic function testing, facilitating cannulation during endoscopic retrograde cholangiopancreatography (ERCP), and gastrinoma testing. In addition, secretions of the pancreatic fluid after secretin stimulation can be used in situ for imaging modalities such as magnetic resonance cholangiopancreatography (MRCP), computerized tomography (CT), and endoscopic ultrasound (EUS).
ChiRhoStim injection is available as a lyophilized sterile powder in 16mcg and 40mcg vials.
For more information call (301) 476-8388 or visit www.chirhostim.com.